The prognostic role of lactate in patients who achieved return of spontaneous circulation after cardiac arrest: A systematic review and meta-analysis Dongni Ren, Xin Wang, Yanyang Tu Cancer Translational Medicine 2019 5(1):1-9 Aim: The aim of the study is to conduct a systematic review and meta-analysis of data showing the association of lactate levels with mortality and neurologic outcome in patients who achieved return of spontaneous circulation (ROSC) after cardiac arrest. Methods: An electronic search of PubMed, Embase, Web of Science, and Cochrane Library databases was conducted. Lactate levels at 0, 6, 12, 24, and 48 h after ROSC in survivors versus nonsurvivors and in good versus poor neurologic outcome patients were extracted. Continuous variable and odds ratio were applied for data analysis. Inverse-variance fixed effects model with 95% confidence interval (CI) was used depending on interstudy heterogeneity. Results: A total of 18 articles meeting the study criteria were included for systematic review and 15 for meta-analysis. The results showed that initial serum lactate levels in nonsurvivors were significantly higher than survivors (standardized mean difference [SMD] = −0.43; 95% CI = [−0.52, −0.33]; P < 0.00001), and a higher lactate level at admission was associated with increased hospital mortality. In addition, initial serum lactate levels were significantly higher in poor neurologic outcome patients than good neurologic outcome patients (SMD = −0.44; 95% CI = [−0.54, −0.34]; P < 0.00001), and initial higher lactate level was associated with poor neurologic outcome. There was a statistically significant difference in lactate levels at 6, 12, 24, and 48 h after ROSC, among survivors versus nonsurvivors and among patients presenting good neurologic outcome versus poor neurologic outcome. However, the included studies had small sample size and highly inconsistent data. Conclusions: Higher lactate levels were associated with increased mortality and poor neurologic outcome. Lower lactate levels or faster lactate clearance was associated with higher survival and good neurologic outcome. |
Inhibitory effect of hyaluronidase-4 in a rat spinal cord hemisection model Xipeng Wang, Mitsuteru Yokoyama, Ping Liu Cancer Translational Medicine 2019 5(1):10-16 Objective: In this study, the effects of anti-hyaluronidase-4 (Hyal-4) antibody on the histological changes of Hyal-4 and the corresponding chondroitin sulfate proteoglycan (CSPG) expression in the rat spinal cord hemisection model were examined. Methods: After creating a rat spinal cord hemisection injury, experiments were conducted by administering anti-Hyal-4 antibody or control immunoglobulin G by intraspinal injection as a single dose, or intrathecal administration, using osmotic pumps, as multiple doses. Frozen sections of the injured spinal cord were made after a single-dose administration on days 1 and 4 and 1 week or at 1, 2, 3, and 4 weeks after the start of pump-aided injections. Immunofluorescence studies were then conducted using CS56 for CSPGs and anti-glial fibrillary acidic protein antibody for reactive astrocytes. Results: No difference was observed between the test and control groups in the single-dose administration of the antibody. In pump-aided administration, CSPGs in the control group decreased at 4 weeks, but those in the anti-Hyal-4 antibody administered group did not. Conclusion: Persistent suppression of Hyal-4 allowed CSPGs to remain and also increase in the rat spinal cord hemisection model, confirming Hyal-4 as an endogenous digestive enzyme of CSPGs. |
Research and development of anticancer agents under the guidance of biomarkers Xiaohui Xu, Guoyu Qiu, Lupeng Ji, Ruiping Ma, Zilong Dang, Ruling Jia, Bo Zhao Cancer Translational Medicine 2019 5(1):17-21 At present, cancer ranks first as the cause of death in the world, necessitating the need to develop new anticancer agents. As a probe, biomarkers can indicate the biological and pharmacological activity of anticancer agents and are thus valuable in predicting their effectiveness during the research and development phase. This paper reviews the research on the biomarker-guided prediction of the efficacy of anticancer agents. We infer that, in the process of the development of anticancer agents, reasonable selection of biomarkers can improve the accuracy of the development of anticancer agents. |
Idiopathic hypereosinophilic syndrome and disseminated intravascular coagulation Mansoor C Abdulla Cancer Translational Medicine 2019 5(1):22-23 |
Αρχειοθήκη ιστολογίου
-
►
2023
(256)
- ► Φεβρουαρίου (140)
- ► Ιανουαρίου (116)
-
►
2022
(1695)
- ► Δεκεμβρίου (78)
- ► Σεπτεμβρίου (142)
- ► Φεβρουαρίου (155)
-
►
2021
(5507)
- ► Δεκεμβρίου (139)
- ► Σεπτεμβρίου (333)
- ► Φεβρουαρίου (628)
-
►
2020
(1810)
- ► Δεκεμβρίου (544)
- ► Σεπτεμβρίου (32)
- ► Φεβρουαρίου (28)
-
▼
2019
(7684)
- ► Δεκεμβρίου (18)
- ► Σεπτεμβρίου (53)
-
▼
Μαρτίου
(258)
-
▼
Μαρ 28
(29)
- Quality of Care
- Sleep Disorders
- Philosophy of Medicine
- Health Technology
- Cancer
- Head and Neck
- Genes,Genomics
- Environmental Research and Public Health
- MDPI Publishing
- Sahel Medical Journal
- Cardiology
- Hamdan Medical Journal
- Forensic Science and Medicine
- Psychiatry
- Association between aortic aneurysm and ulcerative...
- Sarcomatoid carcinoma of the pyriform sinus
- Pea Protein Hydrolysates
- Milk-based oral formulations of ibuprofen
- Pharmaceutical Sciences
- Medical Sciences
- Ophthalmology
- Cancer Translational Medicine
- Bio-Engineering
- Dermatologica Sinica
- Anatomy Pathology
- Anaesthesia
- Allergy
- Yoga ,Philosophy, Psychology ,Parapsychology
- Wound Repair and Regeneration,Plastic Surgery
-
▼
Μαρ 28
(29)
- ► Φεβρουαρίου (2841)
- ► Ιανουαρίου (2803)
-
►
2018
(31838)
- ► Δεκεμβρίου (2810)
- ► Σεπτεμβρίου (2870)
- ► Φεβρουαρίου (2420)
- ► Ιανουαρίου (2395)
-
►
2017
(31987)
- ► Δεκεμβρίου (2460)
- ► Σεπτεμβρίου (2605)
- ► Φεβρουαρίου (2785)
- ► Ιανουαρίου (2830)
-
►
2016
(5308)
- ► Δεκεμβρίου (2118)
- ► Σεπτεμβρίου (877)
- ► Φεβρουαρίου (41)
- ► Ιανουαρίου (39)
Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174
Πέμπτη 28 Μαρτίου 2019
Cancer Translational Medicine
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου